Company Overview of JLL Partners
JLL Partners is a private equity firm specializing in investments in middle market companies. The firm prefers to invest in balance sheet restructurings, debt financing, buyouts, recapitalization, corporate divestitures, operational turnarounds, acquisitions, bolt-on acquisitions, add-on acquisitions, industry consolidations, and strategic co-investments. It invests in companies which are significantly over-leveraged; companies lacking committed sponsorship; companies requiring strategic and/or operational refocusing; companies in out-of-favor industries; businesses being divested from a larger corporate entity; and companies seeking a financial partner to pursue their strategies. The firm s...
450 Lexington Avenue
New York, NY 10017
Founded in 1988
Key Executives for JLL Partners
Co-Founder, Managing Director, and Managing Partner
Managing Director, Head of Investor Relations
Managing Director and member of Investment Committee
Managing Director and Member of Investment Committee
Compensation as of Fiscal Year 2015.
JLL Partners Key Developments
DPx Holdings Plans IPO
Jun 8 15
JLL Partners -backed DPx Holdings B.V. filed plans for an initial public offering, according to a filing with the Securities and Exchange Commission. The number of shares on offer and the price range for the IPO haven't yet been determined, according to the regulatory filing. The document lists a proposed maximum offering amount of $100 million, a figure often used as a place holder in regulatory filings made before the announcement of the number of shares being offered and their potential price range.
JLL Partners, Inc Partners to Form Joint Venture with Royal DSM N.V
Nov 19 13
JLL Partners Inc. has agreed to form a joint venture with Royal DSM N.V. The new company (NewCo), which will be 51% owned by JLL and 49% by DSM, will be a contract development and manufacturing organization (CDMO) for the pharmaceutical industry. NewCo will be formed by combining DSM's business group DSM Pharmaceutical Products (DPP) with JLL's portfolio company Patheon Inc. NewCo will operate as an independent standalone company with about 8,300 employees. JLL will contribute $489 million in cash to NewCo, and DSM will contribute DSM Pharmaceutical Products (DPP) and receive a seller note of $200 million, thereby valuing DPP at $670 million. NewCo has entered into a definitive agreement to effect a plan of arrangement pursuant to the Canada Business Corporations Act (POA) with Patheon under which NewCo would acquire Patheon for $9.32 per share in cash resulting in; a total enterprise value for Patheon of approximately $1,950 million; 64% premium to Patheon's closing share price on November 18, 2013. The transaction is expected to close in first half of 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries